Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Psychiatr Hung ; 36(2): 213-224, 2021.
Article in English | MEDLINE | ID: mdl-33870908

ABSTRACT

No abstract available.


Subject(s)
Mental Disorders , Psychotic Disorders , Humans
2.
Orv Hetil ; 161(31): 1293-1301, 2020 08.
Article in Hungarian | MEDLINE | ID: mdl-32750018

ABSTRACT

INTRODUCTION: Lupus nephritis is the most severe complication of systemic lupus erythematosus (SLE), its development and the effectiveness of immunosuppressive therapy substantially influence patients' quality of life and survival. AIM: In this retrospective observational investigation, the long term-outcome of patients with lupus nephritis, followed at the St. Margit Hospital Immunonephrological Outpatient Clinic, was evaluated. RESULTS: Between 1997 December 1 and 2019 April 30, 73 patients (age 33.7 ± 15 years, 82% female, 18% male) were under care with median observation of 119 [between 3-264] months. At diagnosis, eGFR showed 68 [7-120] ml/min, proteinuria was 2800 [23-16812] mg/day; 10 patients needed dialysis treatment acutely. Renal biopsy, performed in 68 patients, proved proliferative lupus nephritis in 55 and pure membranous lupus nephritis in 6 patients. Administering combined immunosuppressive therapy, complete remission was achieved in 50 and partial remission in 21 cases; one or repeated relapses developed in 28 subjects. Two patients, by the time they got under our care, had already required chronic dialysis, and in the long term, three more patients progressed to end-stage renal disease requiring renal replacement therapy. Renal function stabilized in all other participants, clinical activity of SLE, SLEDAI score, complement levels and immunserology results improved significantly. CONCLUSIONS: Lupus nephritis can be effectively treated by combined induction and prolonged maintenance immunosuppression, but to prevent progression of the disease, long-term care is necessary by co-operation of nephrologist and immunologist. To provide adequate prevention and therapy of the SLE's multiorgan involvement and also the potential complications of immunosuppression, multidisciplinary team is needed with all specialists who may facilitate these patients' complex care. For the long-term management of patients with lupus nephritis, the nephrologists have to be responsible, and the multidisciplinary teams also have to be under their direction. Orv Hetil. 2020; 161(31): 1293-1301.


Subject(s)
Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/complications , Lupus Nephritis/drug therapy , Adult , Aged , Female , Humans , Immunosuppressive Agents/administration & dosage , Long-Term Care , Lupus Nephritis/immunology , Lupus Nephritis/psychology , Male , Middle Aged , Quality of Life , Retrospective Studies , Treatment Outcome
3.
BMC Nephrol ; 18(1): 76, 2017 02 23.
Article in English | MEDLINE | ID: mdl-28231769

ABSTRACT

BACKGROUND: The early identification of patients with ANCA-associated vasculitis (AAV) who are at increased risk for inferior clinical outcome at the time of diagnosis might help to optimize the immunosuppressive therapy. In this study we wanted to determine the predictive value of simple clinical characteristics, which may be applicable for early risk-stratification of patients with AAV. METHODS: We retrospectively analyzed the outcome of 101 consecutive patients with AAV receiving a protocolized immunosuppressive therapy. Baseline Birmingham Vasculitis Activity Score (BVAS) and non-vasculitic comorbidities were computed, then predictors of early (<90 days) and late (>90 days) mortality, infectious death, relapse and end stage kidney disease (ESKD) were evaluated. RESULTS: The baseline comorbidity score independently predicted early mortality (HR 1.622, CI 1.006-2.614), and showed association with infectious mortality (HR 2.056, CI 1.247-3.392). Patients with BVAS at or above median (=21) had worse early mortality in univariable analysis (HR 3.57, CI 1.039-12.243) (p = 0.031), and had more frequent relapses (p = 0.01) compared to patients with BVAS below median. CONCLUSIONS: Assessing baseline comorbidities, beside clinical indices characterizing the severity and extension of AAV, might help clinicians in risk-stratification of patients. Future prospective studies are needed to investigate whether therapies based on risk-stratification could improve both short term and long term survival.


Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/mortality , Infections/mortality , Kidney Failure, Chronic/epidemiology , Aged , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/physiopathology , Comorbidity , Female , Humans , Immunosuppressive Agents/therapeutic use , Logistic Models , Male , Middle Aged , Multivariate Analysis , Proportional Hazards Models , Recurrence , Retrospective Studies , Risk Assessment , Severity of Illness Index
4.
Virchows Arch ; 465(1): 15-24, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24809673

ABSTRACT

The aim of the study was to correlate various primary tumor characteristics with lymph node status, to examine sentinel lymph node (SLN) metastasis size and non-SLN axillary involvement, to look for a cut-off size/number value possibly predicting additional axillary involvement with more accuracy and to examine the relationship of SLN metastasis size to overall survival. Of 301 patients who underwent SLN biopsy, 75 had positive SLNs. The size of the metastases was measured. For different size categories, association with the prevalence of non-SLN metastases was assessed. Associations between metastasis size and tumor characteristics and overall survival (OS) were studied. The prevalence of axillary lymph node (ALN) involvement was not significantly different between cases with micrometastasis or macrometastasis in SLNs (p = 0.124). However, for metastases larger than 6, 7, and 8 mm, the prevalence of ALN involvement was significantly higher (p = 0.046, 0.022, and 0.025). OS was significantly lower in SLN-positive than in SLN-negative cases (p = 0.0375). Primary tumor size larger than 20 mm was associated with a significantly higher incidence of SLN metastasis (p < 0.001), and primary tumor size over 26 mm was associated with additional positive non-SLN (p < 0.001). Higher mitotic index (≥ 7) in primary tumors was significantly (p < 0.001) associated with ALN involvement in SLN-positive cases, whereas higher Ki67 labeling index was not significantly correlated with SLN or ALN involvement. Lymphovascular invasion (LVI) in primary tumors was significantly correlated with SLN positivity (p < 0.001) but not with further ALN involvement or OS. Tumor size and LVI are predictive for SLN metastasis. Mitotic index, primary tumor size, and larger volume SLN involvement are determinants of further ALN involvement. SLN metastasis size over 6 mm is a strong predictor of further axillary involvement. OS is shorter in the presence of positive SLN.


Subject(s)
Breast Neoplasms/pathology , Lymphatic Metastasis/pathology , Sentinel Lymph Node Biopsy , Axilla , Breast Neoplasms/mortality , Carcinoma, Ductal, Breast/pathology , Female , Humans , Middle Aged , Mitotic Index , Neoplasm Micrometastasis/pathology , Prognosis , Survival Analysis
5.
Int Urol Nephrol ; 46(8): 1595-600, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24756532

ABSTRACT

BACKGROUND: Older age is independently associated with mortality in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). We hypothesized that a reduced-dose immunosuppressive treatment would result in similar effectiveness and comparable treatment-related morbidity in elderly patients as the regular dose in younger patients. We also postulated that the higher baseline comorbidities may contribute to the higher mortality of the elderly subjects. METHODS: Ninety-three consecutive patients with AAV between 1998 and 2012 were retrospectively analyzed. Forty-one individuals were defined as "elderly" (age >65 years) and 52 as "younger" (age <65 years). All cause and cardiovascular mortality, death due to vasculitis and infections, and effectiveness of "reduced-dose" immunosuppressive treatment in the elderly group were compared to the effects of "full-dose" treatment in younger individuals. RESULTS: Mortality in the elderly group was higher (p = 0.007). Cardiovascular death was significantly increased (p = 0.002) in the elderly, but mortality due to vasculitis or infections was comparable. Treatment effectiveness was also similar in elderly and younger patients. At the end of the first follow-up year, 37 % of the elderly and 27 % of the younger patients died (p = 0.22). In univariate Cox regression analyses, being older than 65 year, having cardiovascular disease at baseline, need for dialysis at diagnosis, and lower serum albumin were associated with an increased hazard of mortality. CONCLUSIONS: Delivering reduced dose of immunosuppression for elderly patients was associated with satisfactory outcome and favorable treatment-related complication profile. The higher mortality in the elderly could be attributed mainly to baseline cardiovascular morbidity.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/mortality , Cardiovascular Diseases/mortality , Immunosuppressive Agents/administration & dosage , Infections/mortality , Age Factors , Aged , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood , Azathioprine/administration & dosage , Comorbidity , Cyclophosphamide/administration & dosage , Drug Therapy, Combination , Female , Humans , Male , Methylprednisolone/administration & dosage , Middle Aged , Recurrence , Remission Induction , Renal Dialysis , Renal Insufficiency/therapy , Retrospective Studies , Serum Albumin/metabolism
6.
Pathol Oncol Res ; 14(3): 281-4, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18493873

ABSTRACT

Here we report a case of a 73-year-old man with primary intravascular large B-cell lymphoma localized to the prostate. Total prostatectomy was performed due to a benign adenoma suggested by ultrasonography. The diagnosis of IVLBL was obtained incidentally from the prostatectomy specimen. Eight months after the initial R-CHOP chemotherapy a relapse was detected in the left inguinal lymph node, where histologic examination revealed common diffuse large B-cell lymphoma with minimal intravascular component. The second complete remission was achieved by R-IEV therapy. Five months later a second relapse occurred and the patient died in the widespread disease and pneumonia. Primary prostate IVLBL is extremely uncommon; to date only four cases have been described. This is a well documented case, where we also confirmed that the initial primary IVLBL and the secondary lymph node involvement are clonally related. Successful treatment depends on early diagnosis of IVLBL, aggressive chemotherapy and the fact that IVLBL should be considered as a generalized disease in spite of negative staging results.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, B-Cell/drug therapy , Prostatic Neoplasms/drug therapy , Aged , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Combined Modality Therapy , Epirubicin/administration & dosage , Etoposide/administration & dosage , Fatal Outcome , Humans , Ifosfamide/administration & dosage , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell/surgery , Male , Prostatectomy , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Rituximab , Survival
7.
Int J Colorectal Dis ; 21(5): 461-4, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16133001

ABSTRACT

Rarely, carcinoma arises from the fistulous tract of Crohn's disease. Adequate radiological examination often produces misleading pseudonegative findings. We reported two cases of fistula cancers treated with infliximab. The short time-span between the administration of this drug and the diagnosis of cancer makes the correlation between the two unlikely.


Subject(s)
Carcinoma/etiology , Crohn Disease/complications , Intestinal Fistula/complications , Intestinal Neoplasms/etiology , Adult , Carcinoma/pathology , Female , Humans , Intestinal Neoplasms/pathology , Male , Middle Aged
8.
Orv Hetil ; 146(43): 2223-6, 2005 Oct 23.
Article in Hungarian | MEDLINE | ID: mdl-16323569

ABSTRACT

The authors review a case of a 24-year-old male patient hospitalised for repeated acute abdominal symptoms. His medical history included no diseases worth of mentioning. By imaging techniques (abdominal US and CT scan) a cystic lesion, measuring 40 x 35 x 30 mm in diameter was found, and was diagnosed as pseudocyst in the region of the tail of the pancreas. Jejunal feeding was introduced. The lesion did not improve and the second CT scan suggested a suspicion of pancreatic cystadenoma. Three months after first presentation the surgical resection was performed. The tumour, however, was found independent of the pancreas (90 x 80 x 50 mm). Both histologically and immunohistochemically the lesion proved to be the metastasis of a germ cell (yolk-sac) tumour. Following the morphological diagnosis, detailed urological and medical check up was performed. A previously nonpalpable small tumour was found in the left testis which was radically resected. The testicular tumour measuring 9 x 9 x 5 mm in diameter was diagnosed as embryonal carcinoma. Later on the patient underwent chemotherapy. He has been undergoing close oncological followup. Clinically, he is disease free. Authors emphasize the importance of imaging techniques and fine needle aspiration cytology in the case of retroperitoneal masses in young males. The possibility of a metastasis, especially of germ cell origin, should be excluded (not only by physical examination, but by ultrasound of testis also) in case of retroperitoneal cystic tumours even with unusual morphology.


Subject(s)
Endodermal Sinus Tumor/diagnosis , Endodermal Sinus Tumor/secondary , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/secondary , Pancreatic Pseudocyst/diagnosis , Testicular Neoplasms/diagnosis , Adult , Biopsy, Fine-Needle , Diagnosis, Differential , Endodermal Sinus Tumor/pathology , Endodermal Sinus Tumor/surgery , Humans , Immunohistochemistry , Male , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgery , Pancreatic Pseudocyst/pathology , Pancreatic Pseudocyst/surgery , Testicular Neoplasms/pathology , Testicular Neoplasms/surgery , Tomography, X-Ray Computed
9.
Orv Hetil ; 144(49): 2425-7, 2003 Dec 07.
Article in Hungarian | MEDLINE | ID: mdl-14725210

ABSTRACT

Anabolic steroids and creatine supplementation is one of the current abuse used by body builders. It is less known that this combination beside of many deleterious effects may also cause renal damage. Authors report a case of diffuse membranoproliferative glomerulonephritis type I in a 22-year-old man who had been taking continuously methandion in a large quantity and 200 grams of creatine daily, and was sent to the outpatient nephrologic unit with typical clinical signs of nephrosis syndrome. They also call attention to the role of the continuously consumed creatine in the renal failure.


Subject(s)
Anabolic Agents/adverse effects , Creatine/adverse effects , Glomerulonephritis, Membranoproliferative/chemically induced , Methandrostenolone/adverse effects , Nephrotic Syndrome/chemically induced , Adult , Anabolic Agents/administration & dosage , Creatine/administration & dosage , Drug Administration Schedule , Glomerulonephritis, Membranoproliferative/complications , Humans , Male , Methandrostenolone/administration & dosage , Self Administration , Severity of Illness Index , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...